No­vo-backed Galec­to Biotech scores €79 mil­lion in Se­ries C fund­ing

Galec­to Biotech has closed a €79 mil­lion Se­ries C fund­ing round that will help ad­vance the de­vel­op­ment of its lead galectin-3 in­hibitor for id­io­path­ic pul­monary …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER